Antioxidative and EROD activities of osajin and pomiferin

Vesela, Daniela; Kubínová, Renata; Muselík, Jan; Žemlička, Milan; Suchý, Václav

doi:10.1016/j.fitote.2003.12.005

Cited by 34 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…141 Therefore, encouraging evidence exists for a potential chemopreventive role for compounds with HDACi activity, although it is noted that these compounds likely exert their effects through multiple mechanisms, including antioxidant activities and reduction of prostaglandin production. 140,142 …”

Section: A Chemopreventive Role For Hdac Inhibitors?mentioning

confidence: 99%

HDACs and HDAC inhibitors in colon cancer

Mariadason¹

2008

Epigenetics

192

190

View full text Add to dashboard Cite

Section: A Chemopreventive Role For Hdac Inhibitors?mentioning

confidence: 99%

HDACs and HDAC inhibitors in colon cancer

Mariadason¹

2008

Epigenetics

192

190

View full text Add to dashboard Cite

“…Ischemia of the kidney tissue might be the direct cause of an acute renal failure. Prenylated isoflavonoid pomiferin is an isolated substance which was only rarely tested in vitro (Veselá et al 2003) or in vivo (Barto‰íková et al 2003Neãas et al 2004;. Its antioxidant effect could be achieved by several mechanisms.…”

Section: Discussionmentioning

confidence: 99%

“…Schneid. (Moraceae) (Veselá et al 2003). In vitro studies of the antioxidant abilities of pomiferin were performed: the peroxynitrite and DPPH (diphenyl-picryl-hydrazyl) radical scavenging activity.…”

mentioning

confidence: 99%

Effects of Pomiferin Premedication on the Antioxidant Status of Rats with Ischemia-Reperfused Kidney

Janoštíková¹,

Bartošíková²,

Nečas³

et al. 2005

Acta Vet. Brno

View full text Add to dashboard Cite

The aim of this study was to analyze the relationship between the antioxidant effect and the dose of pomiferin during a prophylactic administration. The pathological model for an in vivo experiment was the unilateral ischemia-reperfusion of the laboratory rat kidney. The animals were randomly divided into five groups. Pomiferin was administered orally at doses of 5, 10 and 20 mg·kg -1 , in 2 ml of Avicel solution by a gastric sound once a day to three premedicated groups. A placebo -2 ml of 0.5% Avicel solution -was given to the fourth group, and the fifth group was intact. The premedication lasted 15 days and subsequently ischemia of the left kidney was incited under a general anaesthesia for 60 min. The reperfusion lasted 10 min and it was concluded with blood collection from the left ventricle, and the reperfused kidney was recovered. Selected biochemical markers were assessed in blood: superoxide dismutase, glutathione peroxidase, total antioxidant capacity and malondialdehyde. Kidney tissue samples were used for histopathological examination. Biochemical and histopathological results confirmed the anticipated effects of pomiferin. Pomiferin supported the defensive reactions of the system against free radicals and decreased lipid peroxidation in cell membranes. The relation between the effect and the dose of pomiferin was not linear, and some of the assessed differences between the groups were statistically highly significant. The best results of the biochemical examination were achieved after the administration of pomiferin at the dose of 20 mg·kg -1 . The histopathological results confirmed the dose of 5 mg·kg -1 to be the most effective one.

show abstract

“…Osajin ( (302). The biological activity of osajin is thought to have antioxidant properties that can attenuate the myocardial dysfunction provoked by ischemia reperfusion in rats (72).…”

Section: The Inhibitory Mechanisms Of Natural Compounds Against Npc Smentioning

confidence: 99%

Potential Therapeutic Molecular Targets for Nasopharyngeal Carcinoma

Chen¹

2012

Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma

View full text Add to dashboard Cite

Antioxidative and EROD activities of osajin and pomiferin

Cited by 34 publications

References 10 publications

HDACs and HDAC inhibitors in colon cancer

HDACs and HDAC inhibitors in colon cancer

Effects of Pomiferin Premedication on the Antioxidant Status of Rats with Ischemia-Reperfused Kidney

Potential Therapeutic Molecular Targets for Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About